Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Q4 FY18 Earnings Presentation
16 slides from Dr. Reddy's Laboratories's earnings presentation, May 22, 2018
Slide 1: Press Presentation – Q4'18 & FY18
Press Presentation – Q4’18 & FY18 1 | May 22, 2018 | Q4 FY18 Press Meet
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Dr. Reddy's welcomes Mr. Erez Israeli
Dr. Reddy’s welcomes Mr. Erez Israeli Mr. Erez Israeli Chief Operating Officer and Global Head of Generics & PSAI 3 | May 22, 2018 | Q4 FY18 Press Meet
Slide 4: Q4 Financial highlights
Q4 Financial highlights Revenues (` Cr) YoY QoQ Gross profit (% to sales) -1% -7% 3,806 56.3% 3,554 3,535 53.5% 51.2% Q4 FY17 Q3 FY18 Q4 FY18 Q4 FY17 Q3 FY18 Q4 FY18 R&D (` Cr) YoY QoQ EBITDA (` Cr) YoY QoQ -5% -7% -8% -28% 458 467 805 435 630 578 % to % to 12.9 12.3 12.3 17.7 21.2 16.3 Sales Sales
Slide 5: FY18 Financial highlights
FY18 Financial highlights Revenues (` Cr) YoY Gross profit (% to sales) 1% 14,081 14,203 55.6% 53.7% FY17 FY18 FY17 FY18 R&D (` Cr) YoY EBITDA (` Cr) YoY -7% -6% 1,955 2,549 2,408 1,826 % to % to Sales 13.9 12.9 18.1 17.0 Sales FY17 FY18 FY17 FY18 5 | May 22, 2018 | Q4 FY18 Press Meet % Indicates Gr
Slide 6: Q4 FY18: Global Generics revenues of Rs. 2,784 Cr
Q4 FY18: Global Generics revenues of Rs. 2,784 Cr (YoY 4% Decline, QoQ 8% Decline) North America: ` 1,449 Cr Emerging Markets: ` 550 Cr YoY Decline: 6% YoY Decline: 9% QoQ Decline: 10% Europe: ` 171 Cr QoQ Decline: 7% YoY Decline: 17% QoQ Decline: 15% India: ` 614 Cr YoY Growth: 7.5% QoQ Growth: 0.2
Slide 7: FY18: Global Generics revenues of Rs. 11,401 Cr
FY18: Global Generics revenues of Rs. 11,401 Cr (YoY 1% Decline) North America: ` 5,982 Cr Emerging Markets: ` 2,265 Cr YoY Decline: 6% YoY Growth: 8% Europe: ` 822 Cr YoY Growth: 8% India: ` 2,332 Cr YoY Growth: 1% 7 | May 22, 2018 | Q4 FY18 Press Meet
Slide 8: North America Generics
North America Generics YoY QoQ Revenues (` Cr) -6% -10% Market Share Generics filings update Product Dec-17 Mar-18 Filed 10 ANDA during the 1,535 1,607 quarter 1,449 Liposomal Doxorubicin 33% 38% Decitabine 54%^ 54%^ 276 cumulative filings Ezeti+Simva 40% 35% (272 ANDAs, 4 NDAs) Q4 FY17 Q3 FY18 Q4 F
Slide 9: India
India Revenues (` Cr) YoY QoQ 7.5% 0.2% Q4 FY18 Remarks 613 614 571 Normalizing for GST transition related adjustments, YoY growth is @16% Y-O-Y growth driven by higher volumes and new products Q4 FY17 Q3 FY18 Q4 FY18 2 new products launched during the quarter, Protectis & Rebalanz 2,313 2,332
Slide 10: Emerging Markets
Emerging Markets YoY QoQ Revenues (` Cr) -9% -7% 601 590 Q4 FY18 Remarks 700 550 600 147 154 500 Russia 179 111 99 400 115 300 Year-on-year decline of 25%, majorly on account of lower off-take 343 337 200 due to shift in the channel purchasing pattern. 256 100 0 As per IMS, MAT Mar’18, Dr. Reddy
Slide 11: Pharmaceutical Services & Active Ingredients
Pharmaceutical Services & Active Ingredients Revenues (` Cr) YoY QoQ Q4 FY18 Remarks 16% 15% Year-on-year growth driven by key molecules in the API 625 540 544 business Sequentially growth driven by higher sales in custom pharmaceutical business. Q4 FY17 Q3 FY18 Q4 FY18 During the Quarter, we
Slide 12: Capex, R&D & free cash flows
Capex, R&D & free cash flows R&D expenses (` Cr) Capex (` Cr) 1,955 1,202 1,228 1,745 1,783 1,826 1,008 934 925 1,240 FY14 FY15 FY16 FY17 FY18 FY14 FY15 FY16 FY17 FY18 Free cash flow (` Cr) Net Debt / Equity 2,827 0.25 0.24 0.12 1,468 0.03 877 794 607 -0.05 Mar-14 Mar-15 Mar-16 Mar-17 Mar-18 FY14 FY
Slide 13: Key Priorities
Key Priorities Actively work with the regulatory agencies for accelerating the new product approvals Continue on our journey of strengthening the quality systems and processes Strengthening our portfolio across markets, and grow better than the market growth rate Cost optimization and producti
Slide 14: Q&A SESSION
Q&A SESSION 14 | May 22, 2018 | Q4 FY18 Press Meet
Slide 15: THANK YOU
THANK YOU
Slide 16: Contact
CONTACT INVESTOR RELATIONS MEDIA RELATIONS SAUNAK SAVLA saunaks@drreddys.com CALVIN PRINTER calvinprinter@drreddys.com (PH: +91-40-49002135) (Ph: +91-40- 49002121) ………………………………………………………………………………………………………………………………………………………..…………………………..… About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124,
Dr. Reddy's Laboratories — Q4 FY18 Earnings Presentation on 6ix